Topical 0.4% Ketorolac and Vitreoretinal Surgery

Topical 0.4% Ketorolac for the Inhibition of Miosis During Vitreoretinal Surgery: a Randomized, Placebo-controlled, Double-masked Study

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00576329

Enrollment

Registered

2007-12-19

Start date

2006-11-30

Completion date

2007-10-31

Last updated

2014-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery

Keywords

vitreoretinal surgery, ketorolac, Acular, mydriasis

Brief summary

To determine whether use of topical 0.4% ketorolac has any effect on pupil size during vitreoretinal surgery.

Detailed description

Other outcomes will be to assess postoperative pain and inflammation and visual acuity.

Interventions

DRUGKetorolac

Topical use before surgery

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age of 18, routine elective vitrectomy

Exclusion criteria

* history of trauma, uveitis, prior intraocular surgery within 3 months, requirement of mechanical pupil dilation, prior inclusion of other eye

Design outcomes

Primary

Measure	Time frame
Change in pupil size during vitreoretinal surgery	Surgery

Secondary

Measure	Time frame
Postoperative pain and inflammation	1 day

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026